GlobeNewswire by notified

Orrön Energy AB report for the nine months ended 30 September 2022

Share

Highlights

  • Orrön Energy’s first quarter as a pure play renewables company delivered strong financial results with cash flow from operating activities of MUSD 5.4, and net cash of MUSD 10.8 at the end of the period
  • Proportionate1 power generation amounted to 83 GWh for the third quarter 2022 at an average achieved price of EUR 177 per MWh including Slitevind AB’s (publ) (“Slitevind”) production from 1 September 2022, resulting in a proportionate EBITDA of MUSD 10.8
  • With the addition of Slitevind from September 2022, and the additional five transactions completed or signed post the reporting period end, the Company has increased its estimated annual power generation by over 500 GWh since 1 July at an average acquisition price of MUSD 0.9 per MW installed capacity
  • Estimated annual power generation for Orrön Energy’s asset base is currently 700 GWh, further increasing to 800 GWh in 2023 bringing the total power generation in 2024 to 1,100 GWh once Karskruv is online
  • The Karskruv project remains on track to deliver an additional 290 GWh of annual power generation from 2024

All power generation estimates assume average meteorological conditions and may vary from period to period

Financial Summary2
Orrön Energy owns renewables assets directly and through joint ventures and associated companies and is presenting proportionate financials to showcase the net ownership and related results of these assets. The purpose of the proportionate reporting is to give an enhanced insight into the Company’s operational and financial results.



Expressed in MUSD
1 Jan 2022-
30 Sep 2022
9 months
1 Jul 2022-
30 Sep 2022
3 months
Consolidated financials
Revenue2.62.6
EBITDA-2.12.1
Operating profit (EBIT)-2.71.5
Net result28.31.2
Earnings per share – USD0.100.00
Earnings per share diluted – USD0.100.00
Proportionate financials1
Power generation (GWh)16683
Revenue26.915.5
EBITDA12.110.8
Operating profit (EBIT)9.09.1
Average price achieved per MWh (EUR)153177

1 Proportionate financials represent Orrön Energy’s proportionate ownership (net) of assets and related financial results, including joint ventures. For more details see Key Financial Data on page 31 in the Company’s report for the nine months 2022.
2 This table refers to continuing operations. The financial and operational performance of the discontinued operations can be found in the sections Discontinued Operations and in note 6 of the consolidated financial statements in the Company’s report for the nine months 2022.

Comment from Daniel Fitzgerald, CEO of Orrön Energy AB:
“I am excited to report on the third quarter 2022, which has been a fantastic first quarter for us as a pure play renewables company where we have both grown into one of the largest independent renewables companies on Nasdaq Stockholm and delivered strong financial results and cash flow generation.

We made our first transformational deal during the quarter by acquiring the Swedish wind company Slitevind, which added a diversified portfolio of operational wind assets in the Nordics with long-term cash flow and opportunities for re-powering and growth through new projects. It also added a team with greenfield and brownfield experience, operational expertise and the ability to further pursue organic growth opportunities. I am confident that we will be able to realise further value from this portfolio moving forward, and that this will serve as a platform for organic growth for many years to come. We continued delivering on our acquisition led strategy with five additional value accretive transactions, all of which will complete in the fourth quarter of 2022. These six transactions, combined, will add more than 500 GWh of estimated annual power generation to our asset base, further strengthening the cash generation potential of the Company. We acquired these portfolios and assets for an average of MUSD 0.9 per MW installed capacity, which is an attractive price compared to the value of new wind projects today, and we see significant opportunities for follow on transactions within this space.

Electricity prices reached record high levels during the quarter, driven by geopolitical tensions and increased energy demand in Europe, which highlights the need for locally produced, clean energy. As a renewable company we contribute to increasing the share of renewable energy in the Nordics, and our strategy of being fully spot market exposed allows our investors to gain exposure to European power prices. The demand for renewables is set to grow significantly over the coming years, and I believe power prices will continue to remain strong during the coming years.

We delivered strong financial results for the quarter, with proportionate revenues of MUSD 15.5 and proportionate EBITDA of MUSD 10.8. The Company achieved cash flow from operating activities of MUSD 5.4, finished the third quarter with net cash of MUSD 10.8 and has entered into a MEUR 100 credit facility to fund future capital commitments and growth. With the debt capacity of the asset base, there is significant additional financial capacity to fund material transactions in the future.

Power generation was slightly below expectations during the third quarter due to lower than normal wind speeds and low precipitation across the Nordics. Given the nature of our business, and the reliance on nature, we expect to see these fluctuations balance out between the quarters.

Development of the Karskruv wind farm in southern Sweden is progressing on schedule with preparation work ongoing to allow for installation of the wind turbines and the grid connection in the spring and summer of 2023, and the project remains on track for completion at the end of 2023. Karskruv is expected to add an additional 290 GWh to the Company’s estimated annual power generation, which is set to reach over 1.1 TWh from 2024 onwards.

We entered the third quarter in a strong position, and we are exiting it even stronger. With robust financial results, a large portfolio of producing assets and an experienced team we are in a unique position to continue to grow the business and create long-term shareholder value. I want to thank all our shareholders for your loyal support over the last two decades with Lundin Energy and for joining us on our exciting journey towards creating a profitable renewables company of scale.”

Webcast presentation
Listen to Daniel Fitzgerald, CEO and Espen Hennie, CFO commenting on the report and describing the latest developments in Orrön Energy at a webcast held today at 14:00 CET followed by a question-and-answer session.

Registration for the webcast presentation is available on the website and the below link:
https://us06web.zoom.us/webinar/register/WN_QNoHthpBTF62dr7gLD90NA


For further information, please contact:

Robert Eriksson
Director Corporate Affairs and Investor Relations
Tel: +46 701 11 26 15
robert.eriksson@orron.com

Jenny Sandström
Communications Lead
Tel: +41 79 431 63 68
jenny.sandstrom@orron.com


Orrön Energy is an independent, publicly listed (Nasdaq Stockholm: “ORRON”) renewables company within the Lundin Group of Companies. Orrön Energy has a portfolio of high quality, cash flow generating assets in the Nordics and significant financial capacity to fund further growth and acquisitions. With a major shareholder, management and Board with a proven track record of organic growth, Orrön Energy is in a unique position to create shareholder value through the energy transition.


Forward-looking statements
Statements in this press release relating to any future status or circumstances, including statements regarding future performance, growth and other trend projections, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “seek”, “will”, “would” or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that could occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to several factors, many of which are outside the company’s control. Any forward-looking statements in this press release speak only as of the date on which the statements are made and the company has no obligation (and undertakes no obligation) to update or revise any of them, whether as a result of new information, future events or otherwise.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Inteleos to Host Roundtable on Advancing Maternal Health through Point-Of-Care-Ultrasound Certification6.5.2024 23:25:48 CEST | Press release

Global healthcare certification leader convenes experts to discuss ultrasound training and certification as key strategy to reduce maternal mortality ROCKVILLE, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Inteleos, a non-profit global healthcare certification organization, will host a roundtable discussion titled "Advancing Maternal and Fetal Health through POCUS Training and Certification" on May 29 alongside a side event during the WHO World Health Assembly and the AI for Good Global Summit. The roundtable will explore the urgent need to expand point-of-care ultrasound (POCUS) training and certification for frontline maternal health clinicians as a crucial intervention for reducing preventable maternal deaths and achieving UN Sustainable Development Goals, and how to implement to scale. Despite the increased availability of affordable ultrasound technology, there remains a significant training gap that limits access to this diagnostic tool, especially in low-resource areas with high matern

ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release

SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and

Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342

HiddenA line styled icon from Orion Icon Library.Eye